COSCIENS BIOPHARMA INC (CSCI.CA) Stock News
TSX:CSCI - Toronto Stock Exchange - CA22112H1010 - Common Stock - Currency: CAD
CSCI.CA Latest News, Press Relases and Analysis
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer
25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets,...
Mentions: CSCI
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Ongoing streamlined efficiencies...
Mentions: CSCI
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
TORONTO, ONTARIO, April 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science...
Mentions: CSCI
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
TORONTO, ONTARIO, March 19, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science...
Mentions: CSCI
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product
No significant clinical adverse event observed in Phase 1clinical studyPharmacokinetic profile established and range of doses selected for Phase 2a...
Mentions: CSCI
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization
Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost...
Mentions: CSCI
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in...
Mentions: CSCI
COSCIENS Biopharma Announces Change to Board of Directors
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty...
Mentions: CSCI
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty...
Mentions: CSCI
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty...
Mentions: CSCI
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release...
Mentions: CSCI
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 ...
Mentions: CSCI